20210531-全球发展中心-A_Path_to_Resiliency_Mitigating_the_Impacts_of_COVID-19_on_Essential_Medicines_Supply_Chains_43页_1mb

A Path to Resiliency: Mitigating COVID-19 Impacts on Essential Medicines Supply Chains

🔬 Supply Chain Disruptions

• Short-term manufacturing disruptions occurred globally, particularly in API production (China) and finished goods (India). Most disruptions were temporary, with rebounds within 4-5 months.
• India faced export bans and API shortages due to China production delays, but recovery was swift by May/June 2020.
• Shortages were inconsistent across regions and product types, and local buffer stocks masked global supply issues.

⚙️ Data and Transparency Challenges

• Existing data sources (export data, pharmacy sales, surveys) were insufficient for reliable shortage predictions at the national level.
• Proprietary, high-quality data are often opaque, inhibiting early warning systems.
• Proposed solutions include FAIR-compliant data standards and international data sharing.

🔄 Key Lessons

1. Politics and Governance Matter: Production centers like India and China are vulnerable to political tensions and local governance issues.
2. Profit Motive Drives Shortages: Companies prioritize high-margin markets, exacerbating access issues for low-income settings.
3. Global Shocks May Not Equal Local Solutions: Supply disruptions cascade unevenly, meaning local-level factors often determine shortages.

🛠️ Potential Solutions

1. Increase Redundancy: Boost production capacity and stock piles to lower risks from supply shocks, accepting higher costs as a trade-off.
2. Promote Pooled Procurement: Regional pooling could create economies of scale and price transparency, though current efforts face sustainability issues.
3. Expand Local/Regional Manufacturing: Feasible through hub-and-spoke models, requiring harmonized trade and regulatory policies across nations.

🤔 Open Questions

• Who will fund and manage standardized global pharmaceutical data initiatives?
• How to balance price control with maintaining market incentives?
• How to implement reforms in procurement and regulatory systems?

👁️ Limitations

• Data often reflects limited countries or regions; broad cross-country analysis requires richer datasets.
• Short time frame for COVID-specific analysis limits broader applicability.

💎 Takeaways

• Enhance data tools to monitor supply chains at national levels.
• Strengthen political will to harmonize regulations and procurement systems.
• Key priorities include transparency, diversified sourcing, and localized resilience strategies.

📌 Reference: CGD Policy Paper 213